Openbookopenbook
Equity
StockUS listing USDMPHFPINKHealthcareDeep Value

Dermapharm Holding SE(DMPHF) Stock Analysis | Healthcare

USD --+0.00%
Reward51Moderate
Risk47Moderate
75%Data
2.3% dividend yield · Revenue down 5% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 2.13Bn
Reward Ratingⓘ51 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ47 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DMPHF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Dermapharm Holding SE?

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally.

AI Brief Pro

The brief on Dermapharm Holding SE

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Dermapharm Holding SE?

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 2.13B, and a P/E ratio of 17.9x.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (51)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

AVDLMid Cap / 2.1B market cap
Avadel Pharmaceuticals PLC
Compare
SUPNMid Cap / 2.2B market cap
Supernus Pharmaceuticals Inc
Compare
SHNXYMid Cap / 2B market cap
Shandong Xinhua Pharmaceutical Company Limited
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap2.13B
P/E Ratio17.9005
Dividend Yield2.28%
Beta1.005
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.